Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth M Swisher

Showing results (71-80 of 194) with videos related to

Pageof 20
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|July 10, 2010
Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencingTom Walsh, Ming K Lee, Silvia Casadei, et al.
Gynecologic Oncology|August 31, 2016
Neoplastic cellularity is associated with clinical and molecular features of high-grade serous ovarian carcinomaChristopher B Morse, Barbara M Norquist, Maria I Harrell, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 7, 2016
Ultra-deep sequencing detects ovarian cancer cells in peritoneal fluid and reveals somatic TP53 mutations in noncancerous tissuesJeffrey D Krimmel, Michael W Schmitt, Maria I Harrell, et al.
International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists|April 30, 2019
An Alternate Diagnostic Algorithm for the Diagnosis of Intraepithelial Fallopian Tube LesionsMarie E Perrone, Nicholas P Reder, Sergay N Agoff, et al.
The Journal of Clinical Investigation|July 26, 2016
RING domain-deficient BRCA1 promotes PARP inhibitor and platinum resistanceYifan Wang, John J Krais, Andrea J Bernhardy, et al.
Cancer Medicine|May 8, 2018
Safety and pharmacokinetics of veliparib extended-release in patients with advanced solid tumors: a phase I studyTheresa L Werner, Jasgit Sachdev, Elizabeth M Swisher, et al.
Contemporary Clinical Trials|December 29, 2020
Design of a study to implement population-based risk assessment for hereditary cancer genetic testing in primary careDeborah J Bowen, Catharine Wang, Allison M Cole, et al.
Gynecologic Oncology|August 28, 2021
Germline mutations in Black patients with ovarian, fallopian tube and primary peritoneal carcinomasSahana Somasegar, Arielle S Weiss, Barbara M Norquist, et al.
Cancer|July 20, 2012
BRCA1, TP53, and CHEK2 germline mutations in uterine serous carcinomaKathryn P Pennington, Tom Walsh, Ming Lee, et al.
Nature|February 12, 2008
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancersWataru Sakai, Elizabeth M Swisher, Beth Y Karlan, et al.
Pageof 20

Showing results (71-80 of 194) with videos related to

Sort By:
Pageof 20
Proceedings of the National Academy of Sciences of the United States of America|July 10, 2010
Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencingTom Walsh, Ming K Lee, Silvia Casadei, et al.
Gynecologic Oncology|August 31, 2016
Neoplastic cellularity is associated with clinical and molecular features of high-grade serous ovarian carcinomaChristopher B Morse, Barbara M Norquist, Maria I Harrell, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 7, 2016
Ultra-deep sequencing detects ovarian cancer cells in peritoneal fluid and reveals somatic TP53 mutations in noncancerous tissuesJeffrey D Krimmel, Michael W Schmitt, Maria I Harrell, et al.
International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists|April 30, 2019
An Alternate Diagnostic Algorithm for the Diagnosis of Intraepithelial Fallopian Tube LesionsMarie E Perrone, Nicholas P Reder, Sergay N Agoff, et al.
The Journal of Clinical Investigation|July 26, 2016
RING domain-deficient BRCA1 promotes PARP inhibitor and platinum resistanceYifan Wang, John J Krais, Andrea J Bernhardy, et al.
Cancer Medicine|May 8, 2018
Safety and pharmacokinetics of veliparib extended-release in patients with advanced solid tumors: a phase I studyTheresa L Werner, Jasgit Sachdev, Elizabeth M Swisher, et al.
Contemporary Clinical Trials|December 29, 2020
Design of a study to implement population-based risk assessment for hereditary cancer genetic testing in primary careDeborah J Bowen, Catharine Wang, Allison M Cole, et al.
Gynecologic Oncology|August 28, 2021
Germline mutations in Black patients with ovarian, fallopian tube and primary peritoneal carcinomasSahana Somasegar, Arielle S Weiss, Barbara M Norquist, et al.
Cancer|July 20, 2012
BRCA1, TP53, and CHEK2 germline mutations in uterine serous carcinomaKathryn P Pennington, Tom Walsh, Ming Lee, et al.
Nature|February 12, 2008
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancersWataru Sakai, Elizabeth M Swisher, Beth Y Karlan, et al.
Pageof 20